NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	Bimekizumab	Bimekizumab in different dosages (dose 1 and 2).
DRUG	Adalimumab	Adalimumab in different dosages (dose 1, 2 and 3).
OTHER	Placebo	Placebo will be provided matching Bimekizumab.

Timeline

• Start date: 2017-09-22
• Primary completion: 2018-11-23
• Completion: 2019-02-21
• First posted: 2017-08-14
• Last updated: 2022-04-11
• Results posted: 2022-02-09

Locations

31 sites across 8 countries: United States, Australia, Belgium, Denmark, Germany, Greece, Norway, Russia

Regulatory

• FDA-regulated drug study